Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport Express Cryogenic HV3 Shipping System (HV3); Smartpak II Condition Monitoring System and Tec4Med; Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport System Bioservices, such as controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release services. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPD, a temperature-controlled logistics solution; MVE Biological Solutions Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is based in Brentwood, Tennessee.

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYRX	$9.76	+5.74%	0.47M
3
4
5

CryoPort Inc. (CYRX) Dividend History

Get CryoPort Inc. Data in Excel

More CYRX Financial Data